PROTIP MEDICAL

Their core work

PROTIP MEDICAL is a French medical device SME based in Strasbourg that develops diagnostic and monitoring technologies for clinical conditions affecting the upper digestive tract. Their core product focus is on wearable, non-invasive devices that use acoustic signal analysis to detect and monitor swallowing disorders (dysphagia) — a condition affecting millions of patients post-stroke, post-surgery, and in aging populations. They also bring applied expertise in biomaterial safety evaluation, including cytotoxicity, genotoxicity, and biomaterial-tissue interaction assessment relevant to implantable or ingestible device regulation. Their dual competence — device development and biomaterial risk compliance — positions them well at the intersection of MedTech product development and EU regulatory pathways.

What they specialise in

How they've shifted over time

In their first documented H2020 engagement (2018), PROTIP participated in PANBioRA, a large consortium RIA focused on upstream biomaterial science — risk assessment frameworks, immune profiling, and biocompatibility standardization. This suggests an early phase where the company was building regulatory and scientific credibility by embedding itself in foundational biomaterial safety research. By 2019, the focus had pivoted sharply toward a concrete commercial product: SWALLIS, a wearable sound-based dysphagia monitor that PROTIP themselves coordinated under the SME Instrument Phase 1. The trajectory is clear — from contributor in multi-partner research to independent product developer pursuing market validation for a proprietary diagnostic device.

PROTIP MEDICAL is transitioning from a scientific partner role in regulatory research toward independent MedTech product commercialization, with SWALLIS representing their core go-to-market asset in swallowing disorder diagnostics.

How they like to work

PROTIP shows a split collaboration profile: they joined a large 19-partner RIA consortium (PANBioRA) as a specialized SME contributor, then stepped up to coordinate a smaller, focused SME Instrument project on their own technology. This suggests they are comfortable both as a niche expert within large consortia and as a lead when pursuing their own product roadmap. The SME Instrument coordination in particular signals the ambition and capability to drive a project independently, not just contribute expertise on request.

PROTIP has built connections across 19 unique consortium partners spanning 11 countries through just two projects, indicating they plugged into a broad, internationally diverse research network via PANBioRA. Their geographic reach is genuinely European, though Strasbourg's position on the French-German border likely anchors many of their closest institutional relationships.

What sets them apart

PROTIP MEDICAL occupies a specific niche: a MedTech SME that combines hands-on biomaterial compliance science with proprietary acoustic diagnostic hardware development — a combination rare enough to make them a valuable bridge between device manufacturers and regulatory researchers. Their Strasbourg base situates them in one of Europe's strongest ENT and hospital technology clusters, with proximity to major academic medical centers and the broader Franco-German MedTech corridor. For consortium builders, they offer the credibility of an SME that has both participated in rigorous multi-partner RIA science and successfully led an SME Instrument project, demonstrating they can function at both ends of the TRL spectrum.

Highlights from their portfolio

• PANBioRA
  The largest funded project in their portfolio (€464k), this multi-partner RIA gave PROTIP deep exposure to biomaterial risk assessment methodologies including microfluidics, immune response profiling, and standardization frameworks directly relevant to EU medical device regulation.
• SWALLIS
  Coordinated by PROTIP themselves under the competitive SME Instrument Phase 1, this project marks the company's step into independent product commercialization with a wearable sound-based dysphagia diagnostic device — their clearest statement of proprietary technology ambition.